AstraZeneca PLC (AZN) annual results, year to 31 December 2019: revenue USD 24,384 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2019 it reported revenue of USD 24,384 million, up 10.4% on the year before. Its profit attributable to shareholders was USD 1,335 million, down 38.1%, and diluted earnings per share USD 1.03.
The year to 31 December 2019, against the year before
| Year to | Dec 2018 | Dec 2019 |
|---|---|---|
| Revenue | 22,090 | 24,384 |
| Cost of sales | 4,936 | 4,921 |
| Gross profit | 17,154 | 19,463 |
| Research and development | 5,932 | 6,059 |
| Selling, general and administrative | 10,031 | 11,682 |
| Operating profit | 3,387 | 2,924 |
| Finance costs | 1,419 | 1,432 |
| Profit before tax | 1,993 | 1,548 |
| Income tax | -57.0 | 321 |
| Profit for the year | 2,050 | 1,227 |
| Profit attributable to shareholders | 2,155 | 1,335 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2018 | Dec 2019 |
|---|---|---|
| Cash from operations | 2,618 | 2,969 |
| Purchase of property, plant and equipment | 1,043 | 979 |
| Free cash flow | 1,575 | 1,990 |
| Dividends paid | 3,484 | 3,592 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2018 | Dec 2019 |
|---|---|---|
| Total assets | 60,651 | 61,377 |
| Equity attributable to shareholders | 12,468 | 13,127 |
| Cash and cash equivalents | 4,831 | 5,369 |
| Borrowings, as filed | 19,113 | 18,227 |
| Lease liabilities | n/a | 675 |
| Trade and other receivables | 5,574 | 5,761 |
| Inventories | 2,890 | 3,193 |
| Goodwill | 11,707 | 11,668 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2018 | Dec 2019 |
|---|---|---|
| Gross margin | 77.7% | 79.8% |
| Operating margin | 15.3% | 12.0% |
| Net margin | 9.8% | 5.5% |
| Free cash flow margin | 7.1% | 8.2% |
| Return on year-end equity | 17.3% | 10.2% |
| Effective tax rate | -2.9% | 20.7% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019, this page
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2019, filed 22 February 2022, accession 0001104659-22-025720: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.